Study features that predict benefit from extra immunotherapy in melanoma
Part of Cancer, Skin clinical trials.
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that is stage II, III, or IV, and it was removed with surgery
- You received adjuvant immunotherapy after surgery during 2019–2029
- You are age 18 or older
- You agree to let researchers use your biological (tumor/blood) samples
- You have tumor samples stored at the study’s biobank center
- You have read the study information sheet and are willing to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.